Milan: downside move for Pharmanutra
(Teleborsa) - A negative day for the pharmaceutical company specialized in the development of nutraceutical supplements and medical devices as it sheds -2.03%.Looking at the weekly scenario, Pharmanutra lagged the benchmark index's gains, showing a lower performance than the FTSE Italia Mid Cap average.
The medium-term analysis confirms Pharmanutra's positive trend, while the short-term chart shows the beginning of a decline as the stock tests resistance at 54.37. First support is seen at 52.47. Technically, we expect a downward development towards the low of 51.83 in the near term.
These analyses are to be considered solely for information purposes and are not in any way intended to constitute financial advice, a solicitation of funds from the public or the promotion of any form of investment.
(Teleborsa Research Department)
(Teleborsa) 03-14-2025 12:30 PM
